Integrative functional assays, chemical genomics and high throughput screening: Harnessing signal transduction pathways to a common HTS readout

Current Pharmaceutical Design

Volumn 12, Issue 14, 2006, Pages 1717-1729

  Burstein, Ethan S ^a   Piu, Fabrice ^a   Ma, Jian Nong ^a   Weissman, Jacques T ^a   Currier, Erika A ^a   Nash, Norman R ^a   Weiner, David M ^a   Spalding, Tracy A ^b   Schiffer, Hans H ^a   Del Tredici, Andria L ^a   Brann, Mark R ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Fluorescence polarization (FP); G protein coupled receptor (GPCR); GPCR assay; Histone acetylase transfer activity (HAT); Receptor Selection and Amplification Technology

Indexed keywords

CELL RECEPTOR; DRUG;

CELL STIMULATION; DATA ANALYSIS; DRUG RESPONSE; GENE TARGETING; GENE TECHNOLOGY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MULTIGENE FAMILY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; GENOMICS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33646497262     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873662     Document Type: Review

References (127)

1. Drews J. Drug Discovery: A Historical Perspective 2000; Science 287: 1960-1964.
2. Bennett MR. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol 1998; 12: 289-304.
3. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 2002; 11: 265-77.
4. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 2004; 11: 343-58.
5. Deniker P. The neuroleptics: a historical survey. Acta Psychiatr Scand Suppl 1990; 358: 83-7.
6. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial Sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
7. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The Sequence of the human genome. Science 2001; 5507: 1304-1351.
8. Willson TM, Jones SA, Moore JT, Kliewer SA. Chemical-genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev 2001; 21: 513-522
9. Caron PR, Mullican MD, Mashal RD, Wilson KP, Su MS, Murcko MA. Chemogenomics: a gene family approach to parallel drug discover. Drug Discovery World 2001; 2: 57-62
10. Landro JA, Taylor ICA, Stirtan WG, Osterman DG, Kristie J, Hunnicutt EJ, et al. HTS of the new millennium. The role of pharmacology and flexibility. J Pharmacol Toxicol Method 2000; 44: 273-289.
11. Lenz GR, Nash HM, Jindal S. Chemical ligands, genomics and drug discovery. Drug Discovery Today 2000; 5: 145-156
12. Croston GE. Functional and Cell-Based uHTS in Chemical Genomic Drug Discovery. Trends Biotech 2001; 20: 110-115.
13. Hacksell U, Nash N, Burstein ES, Piu F, Croston G, Brann MR. Chemical Genomics: Massively Parallel Technologies for Rapid Lead Identification and Target Validation. Cytotechnology 2002; 28: 3-10.
14. Jensen AA, Spalding TA. Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 2004; 21: 407-20.
15. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, et al. Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 2002; 61: 1297-302.
16. Messier TL, Dorman CM, Brauner-Osborne H, Eubanks D, Brann MR. High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells. Pharmacol Toxicol 1995; 76: 308-11
17. Burstein ES, Hesterberg DJ, Gutkind JS, Brann MR, Currier EA, Messier TL. The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. Oncogene 1998; 24: 1617-23.
18. Piu F, Magnani M, Ader ME. Dissection of the cytoplasmic domains of cytokine receptors involved in STAT and Ras dependent proliferation. Oncogene 2002 21: 3579-91.
19. Burstein ES, Spalding TA, Hill-Eubanks D, Brann MR. Structure-function of muscarinic receptor coupling to G proteins. Random saturation mutagenesis identifies a critical determinant of receptor affinity for G proteins. J Biol Chem 1995; 270: 3141-6.
20. Burstein ES, Spalding TA, Brann MR. The second intracellular loop of the M5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 1998 273: 24322-7.
21. Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR. Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 1998 273: 21563-8.
22. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA 1991; 88: 4703-7.
23. Burstein ES, Brauner-Osborne H, Spalding TA, Conklin BR, Brann MR. Interactions of muscarinic receptors with the heterotrimeric G proteins Gq and G12: transduction of proliferative signals. J Neurochem 1997; 68: 525-33.
24. Weissman JT, Ma JN, Essex A, Gao Y, Burstein ES. G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway. Oncogene 2004 23: 241-9.
25. Ma JN, Currier EA, Essex A, Feddock M, Spalding TA, Nash NR, et al. Burstein ES. Discovery of novel peptide/receptor interactions: identification of PHM-27 as a potent agonist of the human calcitonin receptor. Biochem Pharmacol 2004 67: 1279-84.
26. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002; 3: 928-44.
27. Ghosh RN, Chen YT, DeBiasio R, DeBiasio RL, Conway BR, Minor LK, et al. Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. Biotechniques 2000; 29: 170-5.
28. Oakley RH, Hudson CC, Cruickshank RD, Meyers DM, Payne RE Jr, Rhem SM, et al. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Dev Technol 2002; 1: 21-30.
29. Bertrand L, Parent S, Caron M, Legault M, Joly E, Angers S, et al. The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors GPCRS. J Recept Signal Transduct Res 2002; 22: 533-41
30. Lerner MR. Tools for investigating functional interactions between ligands and G-protein-coupled receptors. Trends Neurosci 1994; 17: 142-146.
31. Nuttall ME, Lee JC, Murdock PR, Badger AM, Wang FL, Laydon JT, et al. Amphibian melanophore technology as a functional screen for antagonists of G-protein coupled 7-transmembrane receptors. J Biomol Screening 1999; 4: 269-278.
32. Jayawickreme CK, Sauls H, Bolio N, Ruan J, Moyer M, Burkhart W, et al. Use of a cell-based, lawn format assay to rapidly screen a 442, 368 bead-based peptide library. J. Pharmacol. Toxicol. Methods 1999; 42: 189-197.
33. Sullivan E, Tucker EM, Dale IL. Measurement of [Ca2+] using the Fluorometric Imaging Plate Reader FLIPR. Methods Mol. Biol 1999; 114: 125-133.
34. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, et al., Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol 1999; 128: 13-20.
35. Stables J, Green A, Marshall F, Fraser N, Knight E, Sautel M, et al., A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal. Biochem 1997; 252: 115-126.
36. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, et al., Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998; 279: 84-88.
37. Kariv I I, Stevens ME, Behrens DL, Oldenburg KR. High throughput quantitation of cAMP production mediated by activation of seven transmembrane domain receptors. J Biomol Screening 1999; 4: 27-32.
38. Terstappen GC, Giacometti A, Ballini E, Aldegheri L. Development of a functional reporter gene HTS assay for the identification of mGluR7 modulators. J Biomol Screening 2000; 5: 255-262.
39. Chiulli AC, Trompeter K, Palmer M. A novel high throughput chemiluminescent assay for the measurement of cellular cyclic adenosine monophosphate levels. J. Biomol Screening 2000; 5: 239-248.
40. Miyawaki A, Llopis J, Heim R, McCaffery JM, Adams JA, Ikura M, et al., Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature 1997; 388: 882-887.
41. Zaccolo M, De Giorgi F, Cho CY, Feng L, Knapp T, Negulescu PA, et al., A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat. Cell Biol 2000; 2: 25-29.
42. Brink CB, Harvey BH, Bodenstein J, Venter DP, Oliver DW. Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol 2004 57: 373-87.
43. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003 99: 25-44.
44. Tucek S, Michal P, Vlachova V. Modelling the consequences of receptor-G-protein promiscuity. Trends Pharmacol Sci 2002 23: 171-6.
45. Hall RA, Premont RT, Lefkowitz RJ. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol 1999; 145: 927-32.
46. Heuss C, Gerber U. G-protein-independent signaling by G-protein-coupled receptors. Trends Neurosci 2000; 23: 469-75.
47. Brzostowski JA, Kimmel AR. Signaling at zero G: G-protein-independent functions for 7-TM receptors. Trends Biochem Sci 2001; 26: 291-7.
48. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 2002; 14: 297-309.
49. Terrillon S, Bouvier M. Receptor activity-independent recruitment of betaarrestin2 reveals specific signaling modes. EMBO J 2004; 23: 3950-3961.
50. Stables J, Green A, Marshall F, Fraser N, Knight E, Sautel M, Milligan G, et al. A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem 1997; 252: 115-26.
51. Sullivan E, Tucker EM, Dale IL. Measurement of [Ca2+] using the Fluorometric Imaging Plate Reader FLIPR;. Methods Mol Biol 1999; 114: 125-33.
52. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 1999; 128: 13-20.
53. Salomon Y. Cellular responsiveness to hormones and neurotransmitters: conversion of [3H]adenine to [3H]cAMP in cell monolayers, cell suspensions, and tissue slices. Methods Enzymol 1991; 195: 22-28.
54. Chen W, Shields TS, Stork PJS, Cone RD. A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. Anal Biochem 1995; 226: 349-54.
55. Potenza MN, Graminski GF, Lerner MR. A method for evaluating the effects of ligands upon Gs protein-coupled receptors using a recombinant melanophore-based bioassay. Anal Biochem 1992; 206: 315-22.
56. Conklin BR, Farfel Z, Lustig KD, Julius D, Bourne HR. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 1993; 363: 274-6
57. Conklin BR, Herzmark P, Ishida S, Voyno-Yasenetskaya TA, Sun Y, Farfel Z, et al. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol Pharmacol 1996; 50: 885-90.
58. Amatruda TT 3rd, Steele DA, Slepak VZ, Simon MI. G alpha 16, a G protein alpha subunit specifically expressed in hematopoietic cells. Proc Natl Acad Sci USA 1991; 88: 5587-91.
59. Offermanns S, Simon MI. G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. J Biol Chem 1995; 270: 15175-80.
60. Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science 1991; 252: 802-8.
61. Strathmann MP, Simon MI. G alpha 12 and G alpha 13 subunits define a fourth class of G protein alpha subunits. Proc Natl Acad Sci USA 1991; 88: 5582-6.
62. Gomeza J, Mary S, Brabet I, Parmentier ML, Restituito S, Bockaert J, et al. Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists. Mol Pharmacol 1996; 50: 923-30.
63. Lee JW, Joshi S, Chan JS, Wong YH Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C. J Neurochem 1998; 70: 2203-11.
64. Kostenis E. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 2001; 22: 560-4.
65. Milligan G. High-content assays for ligand regulation of G-protein-coupled receptors. Drug Discov Today 2003 8: 579-85.
66. Bokoch GM. Interplay between Ras-related and heterotrimeric GTP binding proteins: lifestyles of the BIG and little. FASEB J 1996; 10: 1290-5.
67. Seidel MG, Klinger M, Freissmuth M, Holler C. Activation of mitogen-activated protein kinase by the A2A;-adenosine receptor via a rap1-dependent and via a p21ras;-dependent pathway. J Biol Chem 1999; 274: 25833-41.
68. Schmitt JM, Stork PJS 2000. Beta-adrenergic receptor activates extracellular regulated kinases ERKs; via the small G protein Rap1 and the serine/threonine kinase B-Raf. J Biol Chem 275: 25342-25350.
69. Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J Biol Chem 2002; 277: 12009-15.
70. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by Gi; family members in platelets. J Biol Chem 2002; 277: 23382-90.
71. Guo FF, Kumahara E, Saffen D. A CalDAG-GEFI/Rap1/B-Raf cassette couples M1; muscarinic acetylcholine receptors to the activation of ERK1/2. J Biol Chem 2001; 276: 25568-25581.
72. Quilliam LA, Rebhun JF, Castro AF. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 2002; 71: 391-444.
73. Cherfils J, Chardin P. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 1999; 24: 306-11.
74. de Rooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofer A, et al. Epac is a Rap1 guanine-nuecleotide-exchange factor directly activated by cyclic AMP. Nature 1998; 396: 474-477.
75. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998; 282: 2275-2279.
76. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M. A ras-related gene with transformation suppressor activity. Cell 1989; 56: 77-84
77. Zhang K, Noda M, Vass WC, Papageorge AG, Lowy DR. Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1. Science 1990; 249: 162-5.
78. Van den Berghe N, Cool RH, Wittinghofer A. Discriminatory residues in Ras and Rap for guanine nucleotide exchange factor recognition. J Biol Chem 1999; 274: 11078-85.
79. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001; 41: 145-74.
80. Watts VJ. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 2002; 302: 1-7.
81. Lustig KD, Conklin BR, Herzmark P, Taussig R, Bourne HR. Type II adenylylcyclase integrates coincident signals from Gs, Gi, and Gq. J Biol Chem 1993; 268: 13900-5
82. Kenakin T. Efficacy at G-protein-coupled receptors Nat Rev Drug Discov 2002; 1: 103-10.
83. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998; 95: 9914-9.
84. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 1999; 23: 737-46.
85. He L, Fong J, von Zastrow M, Whistler JL. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002; 108: 271-82.
86. Kenakin T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov 2003; 2: 429-38.
87. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390: 88-91.
88. Michal P, Lysikova M, Tucek S. Dual effects of muscarinic M2; acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol 2001; 132: 1217-28.
89. Jakubik J, Bacakova L, el-Fakahany EE, Tucek S. Constitutive activity of the M1-M4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 1995 377: 275-9.
90. Trejo J. Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 2003; 307: 437-42.
91. Stalheim L, Ding Y, Gullapalli A, Paing MM, Wolfe BL, Morris DR, et al. Multiple Independent Functions of Arrestins in the Regulation of Protease-activated Receptor-2 Signaling and Trafficking. Mol Pharmacol 2005; 67: 78-87.
92. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 2003; 64: 1271-6.
93. Hilf G, Jakobs KH. Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur J Pharmacol 1992; 225: 245-52
94. Nijenhuis WA, Oosterom J, Adan RA. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 2001; 15: 164-71
95. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol Endocrinol 2003; 17: 2201-10
96. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385: 347-50
97. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, Leurs R, et al. Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 2001; 276: 1133-7.
98. Nilsson CL, Eriksson E. Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors? J Neural Transm Gen Sect 1993; 92: 213-20.
99. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 2004; 65: 2-11.
100. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-42.
101. Bakker RA, Casarosa P, Timmerman H, Smit MJ, Leurs R. Constitutively active Gq/11-coupled receptors enable signaling by coexpressed G(i/ o)-coupled receptors. J Biol Chem 2004; 279: 5152-61.
102. Burstein ES, Spalding TA, Brauner-Osborne H, Brann MR. Constitutive activation of muscarinic receptors by the G-protein Gq. FEBS Lett 1995; 363: 261-3.
103. Burstein ES, Spalding TA, Brann MR. Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 1997; 51: 312-9
104. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D, Brann MR. Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 1995 275: 1274-9.
105. Spalding TA, Burstein ES, Wells JW, Brann MR. Constitutive activation of the M5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 1997; 36: 10109-16.
106. Spalding TA, Burstein ES. Constitutively active muscarinic receptors. Life Sci 2001; 68: 2511-6
107. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Related Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002 Mar 29;277(13): 11441-9.
108. Robinson-Rechavi M, Carpentier AS, Duffraisse M, Laudet V. How many nuclear hormone receptors are there in the human genome? Trends Genet 2001 17: 554-6
109. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004 3: 950-64.
110. Sladek R, Giguere V. Orphan nuclear receptors: an emerging family of metabolic regulators. Adv Pharmacol 2000; 47: 23-87.
111. Malaspina A, Pearce RK, Graeber MB. Nuclear hormone and orphan receptors: their role in neuronal differentiation and cytoprotection and in the pathogenesis of Parkinson's disease. Dev Neurosci 2003 6: 375-83.
112. Glickman JF, Wu X, Mercuri R, Illy C, Bowen BR, He Y, et al. A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen 2002 7: 3-10.
113. Wu X, Glickman JF, Bowen BR, Sills MA. Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen 2003 8: 381-92.
114. Parker GJ, Law TL, Lenoch FJ, Bolger RE. Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J Biomol Screen 2000 5: 77-88.
115. Olefsky JM. Nuclear receptor minireview. J Biol Chem 2001 276: 36863-4.
116. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996 10: 1167-77.
117. Hermanson O, Glass CK, Rosenfeld MG Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 2002 13: 55-60.
118. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P. Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR.RARalpha heterodimerization and transcriptional activity. J Biol Chem 1999 274: 38225-31.
119. Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR, et al. Stress pathway activation induces phosphorylation of retinoid X receptor. J Biol Chem 2000 275: 32193-9.
120. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002(138): RE9. Print 2002 Jun 25.
121. Coward P, Lee D, Hull MV, Lehmann JM. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci USA 2001 98: 8880-4.
122. Tremblay GB, Bergeron D, Giguere V. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. Endocrinology 2001 142: 4572-5.
123. Harris JM, Lau P, Chen SL, Muscat GE. Characterization of the retinoid orphan-related receptor-alpha coactivator binding interface: a structural basis for ligand-independent transcription. Mol Endocrinol 2002 16: 998-1012.
124. Tanaka S, Morishita T, Hashimoto Y, Hattori S, Nakamura S, Shibuya M, et al. C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci USA 1994; 91, 3443-3447.
125. Irie K, Nakagawa Y, Ohigashi H. Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes. Curr Pharm Des 2004; 10(12): 1371-85.
126. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004; 10(15): 1827-43.
127. Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des 2005; 11(20): 2577-91.